CPX-351(阿糖胞苷与柔红霉素脂质体注射液)对比传统阿糖胞苷联合柔红霉素治疗老年新诊断继发性急性髓系白血病患者
本项开放标签随机III期试验纳入309例60至75岁新诊断高危/继发性急性髓系白血病患者,比较CPX-351与7+3方案诱导及巩固治疗的疗效与安全性。CPX-351显著延长中位总生存期(9.56个月 vs 5.95个月;HR 0.69;95%CI 0.52-0.90;单侧P=0.003),总缓解率亦显著更高(47.7% vs 33.3%;双侧P=0.016)。非血液学不良事件发生率两组相当,CPX-351安全性特征与7+3相似。
要点
- CPX-351较7+3显著延长老年继发性AML患者中位总生存期(9.56 vs 5.95个月;HR 0.69)。
- CPX-351总缓解率显著高于7+3(47.7% vs 33.3%;双侧P=0.016)。
- 非血液学不良事件发生率两组相当,CPX-351安全性特征与7+3相似。
核心结论
- 在60至75岁新诊断继发性急性髓系白血病患者中,CPX-351治疗较传统7+3方案显著延长生存期。
- CPX-351的安全性特征与传统7+3治疗相似。
研究设计与样本
- 开放标签、随机、III期试验,纳入309例60至75岁新诊断高危/继发性急性髓系白血病患者。
- 患者接受1至2个诱导周期CPX-351或7+3方案,随后接受类似方案的巩固治疗。
- 主要终点为总生存期。
主要发现
- CPX-351较7+3显著改善中位总生存期(9.56个月 vs 5.95个月;风险比0.69;95%CI 0.52至0.90;单侧P=0.003)。
- CPX-351总缓解率显著高于7+3(47.7% vs 33.3%;双侧P=0.016)。
- 各年龄组和AML亚型中均观察到结局改善。
- 非血液学不良事件发生率两组相当,尽管CPX-351治疗期更长且中性粒细胞和血小板计数恢复时间延长。
- 第30天早期死亡率CPX-351组为5.9%、7+3组为10.6%(双侧P=0.149);第60天分别为13.7%和21.2%(双侧P=0.097)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML). Patients and Methods In this open-label, randomized, phase III trial, 309 patients age 60 to 75 years with newly diagnosed high-risk/sAML received one to two induction cycles of CPX-351 or 7+3 followed by consolidation therapy with a similar regimen. The primary end point was overall survival. Results CPX-351 significantly improved median overall survival versus 7+3 (9.56 v 5.95 months; hazard ratio, 0.69; 95% CI, 0.52 to 0.90; one-sided P = .003). Overall remission rate was also significantly higher with CPX-351 versus 7+3 (47.7% v 33.3%; two-sided P = .016). Improved outcomes were observed across age-groups and AML subtypes. The incidences of nonhematologic adverse events were comparable between arms, despite a longer treatment phase and prolonged time to neutrophil and platelet count recovery with CPX-351. Early mortality rates with CPX-351 and 7+3 were 5.9% and 10.6% (two-sided P = .149) through day 30 and 13.7% and 21.2% (two-sided P = .097) through day 60. Conclusion CPX-351 treatment is associated with significantly longer survival compared with conventional 7+3 in older adults with newly diagnosed sAML. The safety profile of CPX-351 was similar to that of conventional 7+3 therapy.
引用
- Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018. PMID: 30024784. doi:10.1200/JCO.2017.77.6112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。